Acorda Therapeutics   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Ardsley NY United States (1995)

Organization Overview

First Clinical Trial
2002
NCT01683838
First Marketed Drug
2010
dalfampridine (ampyra)
First NDA Approval
2010
dalfampridine (ampyra)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ACORDA | Acorda Therapeutics

Active Ingredients

Marketed Drugs (2)

Key: Acorda Therapeutics (1) Acquired (1)

dalfampridine (ampyra) (2010 NDA)

levodopa (larodopa) (2018)

Drugs in Phase 4 Trials (1)

dalfampridine (ampyra) (23 trials)

Drugs in Phase 3 Trials (2)

Key: Acorda Therapeutics (0) Acquired (2)

levodopa (larodopa) (11 trials)

tozadenant (7 trials)

Drugs in Phase 2 Trials (15)

Key: Acorda Therapeutics (5) Acquired (10)

ac105 (1 trial)

ampere (1 trial)

btt-1023 (3 trials)

cocaine (Erythroxyline) (1 trial)

diazepam (valium) (4 trials)

dopamine (intropin) (2 trials)

elb-139 (1 trial)

elb245 (1 trial)

moxifloxacin (avelox) (1 trial)

nepicastat (3 trials)

rufinamide (banzel) (1 trial)

sodium chloride (1 trial)

syn120 (1 trial)

tizanidine (zanaflex) (2 trials)

tolterodine (detrol) (1 trial)

Drugs in Phase 1 Trials (8)

Key: Acorda Therapeutics (6) Acquired (2)

amphetamine (Adderall) (1 trial)

carbidopa (sinemet) (3 trials)

elb353 (1 trial)

glial growth factor 2 (2 trials)

midazolam (versed) (1 trial)

neuregulin (1 trial)

rhigm22 (2 trials)

zolmitriptan (zomig) (2 trials)

Indications

Approved Indications


 

Multiple Sclerosis

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Cerebral Infarction (Phase 2)

Cerebral Palsy (Phase 1)

Drug Resistant Epilepsy (Phase 2)

Epilepsy (Phase 2)

Fatigue (Phase 2)

Heart Failure (Phase 1)

Hepatic Insufficiency (Phase 1)

Ischemia (Phase 4)

Liver Failure (Phase 1)

Migraine Disorders (Phase 1)

Multiple Sclerosis (Phase 4)

Multiple Sclerosis, Relapsing-Remitting (Phase 1)

Muscle Spasticity (Phase 3)

Myelitis (Phase 2)

Myelitis, Transverse (Phase 2)

Neuritis (Phase 3)

Neuromyelitis Optica (Phase 2)

Optic Nerve Diseases (Phase 4)

Optic Neuritis (Phase 3)

Optic Neuropathy, Ischemic (Phase 4)

Parkinson Disease (Phase 3)

Renal Insufficiency (Phase 1)

Respiratory Aspiration (Phase 1)

Sclerosis (Phase 4)

Seizures (Phase 2)

Spinal Cord Injuries (Phase 3)

Stroke (Phase 3)

Ventricular Dysfunction (Phase 1)

Ventricular Dysfunction, Left (Phase 1)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 26